Nurix Therapeutics, Inc. (NRIX) reported quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.73. For comparison, a year earlier the loss was $0.52 per share. These numbers have been adjusted for one-off items.
This quarterly report showed an earnings surprise of -10.96%. A quarter ago, it was expected that this company would post a loss of $0.76 per share when it actually produced a loss of $0.79, delivering a surprise of -3.95%.
Over the last four quarters, the company has surpassed consensus EPS estimates only once.
Nurix Therapeutics, which belongs to the Zacks Medical – Biomedical & Genetics industry, posted revenues of $9.04 million for the quarter ended May 2026, missing the Zacks Consensus Estimate by 36.76%. For comparison, revenues from a year ago amounted to $44.06 million. The company has failed to beat consensus revenue estimates over the last four quarters.
The sustainability of the immediate share price movement based on the recently-released numbers and future earnings expectations will largely depend on management’s commentary on the earnings call.
Nurix Therapeutics shares are up about 28.2% year-to-date compared to the S&P 500 Index’s gain of 9.3%.
What’s next for Nurix Therapeutics?
While Nurix Therapeutics has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
There are no straightforward answers to this key question, but one reliable measure that can support investors address this issue is the company’s earnings prospects. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a mighty correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Prior to the earnings release, the estimate revision trend for Nurix Therapeutics was favorable. While the magnitude and direction of estimate revisions could change following the company’s just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. We can therefore expect that the company’s shares will outperform the market in the near future.
It will be fascinating to see how estimates for the next quarters and the current fiscal year change in the coming days. The current consensus EPS estimate is -$0.72 on revenue of $15.87M for the coming quarter and -$2.88 on revenue of $52.2M for the current fiscal year.
Investors should be aware that the outlook for the industry may also have a significant impact on share prices. In terms of the Zacks Industry Rank, the Medical Biomedical and Genetics industry is currently in the top 43% of over 250 Zacks industries. Our research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
CorMedix (CRMD), another company in the same industry, has not yet reported results for the quarter ended June 2026.
The pharmaceutical and medical device company is expected to post quarterly earnings of $0.26 per share in its upcoming report, representing a year-over-year change of -7.1%. The consensus EPS estimate for the quarter has not changed over the last 30 days.
CorMedix’s revenue is expected to be $94.7 million, up 138.3% from the same quarter last year.
